# OnCo record dipg-dmg (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/dipg-dmg/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "dipg-dmg" ;
  schema:name "Diffuse midline glioma, H3 K27-altered (including DIPG)"@en ;
  schema:alternateName "DIPG"@en, "Diffuse intrinsic pontine glioma"@en, "DMG"@en, "H3 K27M glioma"@en, "Paediatric high-grade glioma"@en ;
  schema:description "Diffuse midline glioma grows through the brainstem and cannot be removed surgically. A single change in a histone protein (H3 K27M) rewires how the tumour reads its DNA. Radiotherapy was long the only help; in 2025 the first drug aimed at this tumour, dordaviprone (ONC201), was approved after durable shrinkage in some patients, and GD2 CAR-T cells have produced striking early responses."@en ;
  schema:url <https://onco.cc/cancers/dipg-dmg/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Diffuse_intrinsic_pontine_glioma> ;
  schema:citation <https://www.cancer.gov/types/brain/hp/child-astrocytoma-treament-pdq>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma>, <https://clinicaltrials.gov/study/NCT05580562>, <https://doi.org/10.1038/s41586-022-04489-4> ;
  onco:tag "nci-coverage", "paediatric", "cns" ;
  onco:related <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/terms/race-for-children-act/>, <https://onco.cc/institutions/accelerate-platform/>, <https://onco.cc/cancers/idh-mutant-astrocytoma/>, <https://onco.cc/cancers/oligodendroglioma/>, <https://onco.cc/cancers/paediatric-high-grade-glioma/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/technologies/bbb-focused-ultrasound/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/palliative-care/> ;
  onco:targets <https://onco.cc/targets/gd2/>, <https://onco.cc/targets/ezh2/> ;
  onco:drugs <https://onco.cc/drugs/dordaviprone/>, <https://onco.cc/drugs/temozolomide/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:institutions <https://onco.cc/institutions/siop-europe/>, <https://onco.cc/institutions/stanford/>, <https://onco.cc/institutions/dkfz/> ;
  onco:pathways <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/h3k27m/>, <https://onco.cc/terms/blood-brain-barrier/>, <https://onco.cc/terms/late-effects/> ;
  onco:trials <https://onco.cc/trials/action-dmg/>, <https://onco.cc/trials/pediatric-match/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-brain-delivery/>, <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-majzner-nature/> ;
  onco:pipeline <https://onco.cc/drugs/dordaviprone/>, <https://onco.cc/trials/action-dmg/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/technologies/bbb-focused-ultrasound/>, <https://onco.cc/trials/pediatric-match/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/action-dmg/>, <https://onco.cc/drugs/dordaviprone/>, <https://onco.cc/drugs/dordaviprone/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/targets/gd2/>, <https://onco.cc/technologies/bbb-focused-ultrasound/>, <https://onco.cc/technologies/palliative-care/> .